BioCentury
ARTICLE | Strategy

Three's company

How NCCN determines affordability in new cancer drug value framework

November 2, 2015 8:00 AM UTC

The National Comprehensive Cancer Network is the third physician group to launch a tool to assess the value of cancer drugs. Unlike the others, which compare drug benefits to a reported price, NCCN is asking panels of doctors to make a subjective judgment of affordability.

On Oct. 16, NCCN unveiled its Evidence Blocks tool, which scores treatment regimens on efficacy, safety, strength of the evidence, consistency of the evidence and affordability on a scale of 1-5...